Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
42 hedge funds and large institutions have $157M invested in Syros Pharmaceuticals, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
20% more funds holding
Funds holding: 35 → 42 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less capital invested
Capital invested by funds: $176M → $157M (-$19.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
+$1.85M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$780K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$379K |
| 4 |
State Street
Boston,
Massachusetts
|
+$287K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$280K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$832K |
| 2 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
-$427K |
| 3 |
Goldman Sachs
New York
|
-$217K |
| 4 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
-$193K |
| 5 |
SIM
Spark Investment Management
New York
|
-$160K |
SYRS Hedge Fund Activity: Q4 2016 in Review
42 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q4 2016, worth a combined $157M — down 11% from $176M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new SYRS positions and 5 closed out — a net gain of 7 holders — while 12 added to existing stakes and 7 trimmed.
The largest buyer was Casdin Capital, adding an estimated $1.85M. The largest seller was Foresite Capital Management III, exiting entirely with an estimated $832K sold.
- 42 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q4 2016, up from 35 in Q3 2016.
- Funds reported $157M of Syros Pharmaceuticals, Inc. Common Stock stock for Q4 2016, down 11% quarter-over-quarter.
- 12 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q4 2016 and 5 closed out, a net change of +7 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q4 2016 was Casdin Capital, an estimated $1.85M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q4 2016 was Foresite Capital Management III, an estimated $832K sold.
Based on aggregated 13F filings for Q4 2016.